How does bupropion (Wellbutrin) inhibit cytochrome P450 2D6 (CYP2D6) and what are the clinical implications for co‑administered CYP2D6 substrate medications?

Bupropion is a Potent CYP2D6 Inhibitor with Significant Clinical Implications

Bupropion and its metabolites—particularly threohydrobupropion and erythrohydrobupropion—are potent CYP2D6 inhibitors that can increase exposure to CYP2D6 substrate medications by 2- to 5-fold, requiring dose reductions of co-administered CYP2D6 substrates, especially those with narrow therapeutic indices. 1

Mechanism of CYP2D6 Inhibition

Bupropion inhibits CYP2D6 through two distinct mechanisms:

1. Direct Competitive Inhibition

• Bupropion itself is a weak CYP2D6 inhibitor in vitro (Ki = 21 μM) 2
• However, its metabolites are far more potent inhibitors:
  • Erythrohydrobupropion: Ki = 1.7 μM (most potent) 2
  • Threohydrobupropion: Ki = 5.4 μM 2
  • Hydroxybupropion: Ki = 13 μM 2

The metabolites circulate at higher concentrations than the parent drug and are primarily responsible for the clinical CYP2D6 inhibition 3, 4. Recent data shows that accurate prediction of the clinical interaction requires accounting for all metabolites and their stereoisomers, particularly when using estimated liver (not plasma) concentrations 3.

2. CYP2D6 Downregulation

Bupropion and its metabolites significantly downregulate CYP2D6 mRNA in hepatocytes in a concentration-dependent manner 4. This transcriptional regulation, combined with reversible inhibition, fully explains the magnitude of clinical drug-drug interactions that cannot be predicted by reversible inhibition alone 4.

Dose-Dependent Inhibition

The CYP2D6 inhibitory effect is clearly dose-dependent 5:

• Bupropion 150 mg/day: Phenoconverts 19% of patients to CYP2D6 poor metabolizer (PM) status
• Bupropion ≥300 mg/day: Phenoconverts 50% of patients to CYP2D6 PM status 5

This dose-dependency is critical when adjusting doses of CYP2D6 substrates during co-administration.

Clinical Implications for Co-Administered Medications

High-Risk CYP2D6 Substrates Requiring Dose Reduction

When initiating bupropion with these medications, reduce the CYP2D6 substrate dose, particularly for drugs with narrow therapeutic indices 1:

Antidepressants

• Venlafaxine (exposure increases 110-132%) 6
• Desipramine (5-fold increase in exposure) 2
• Nortriptyline, imipramine, paroxetine, fluoxetine, sertraline 1

Antipsychotics

• Aripiprazole (5.65-fold increase in AUC in preclinical studies) 7
• Haloperidol, risperidone, thioridazine 1

Cardiovascular Medications

• Metoprolol and other beta-blockers 1
• Type 1C antiarrhythmics (propafenone, flecainide) - particularly concerning due to narrow therapeutic index 1

Medications Requiring Dose Increases

Drugs requiring CYP2D6 activation for efficacy may need dose increases 1:

• Tamoxifen: Reduced conversion to active metabolites may decrease efficacy in breast cancer treatment 8
• Codeine and tramadol: Reduced conversion to active analgesic metabolites 9

The FDA label explicitly states: "Drugs that require metabolic activation by CYP2D6 to be effective (e.g., tamoxifen), theoretically could have reduced efficacy when administered concomitantly with inhibitors of CYP2D6 such as bupropion" 1.

Special Clinical Considerations

Tamoxifen Co-Administration

When SSRIs are needed in tamoxifen-treated breast cancer patients, avoid bupropion (moderate-to-potent CYP2D6 inhibitor). Instead, use mild CYP2D6 inhibitors: sertraline, citalopram, venlafaxine, or escitalopram 8.

Phenoconversion Monitoring

Because of high variability in CYP2D6 inhibition (19-50% phenoconversion depending on dose), therapeutic drug monitoring (TDM) of CYP2D6 substrates should be considered to provide individualized dose adjustments during bupropion co-medication 5.

Seizure Risk Medications

Naltrexone ER/bupropion ER is contraindicated in patients with seizure disorders or high seizure risk, as bupropion lowers the seizure threshold 10. Use extreme caution when combining with other drugs that lower seizure threshold 1.

Age Considerations

The magnitude of the bupropion-CYP2D6 interaction appears independent of patient age, with similar AUC changes predicted in younger (<65 years) and elderly (≥65 years) patients 6.

Common Pitfalls to Avoid

1. Underestimating metabolite contribution: The clinical interaction cannot be explained by bupropion alone—metabolites are the primary drivers 3, 4, 2

2. Ignoring dose-dependency: Higher bupropion doses (≥300 mg/day) cause substantially more CYP2D6 inhibition than lower doses 5

3. Overlooking prodrugs: Remember that codeine and tramadol require CYP2D6 activation and may be ineffective during bupropion co-administration 9

4. Forgetting narrow therapeutic index drugs: Type 1C antiarrhythmics and certain antipsychotics require particular vigilance 1

5. Missing the tamoxifen interaction: This is a critical oncologic concern where reduced tamoxifen efficacy may increase breast cancer recurrence risk 8

Practical Management Algorithm

When starting bupropion in a patient on CYP2D6 substrates:

1. Identify all CYP2D6 substrates the patient is taking
2. Assess therapeutic index: Narrow therapeutic index drugs (antiarrhythmics, some antipsychotics) require immediate dose reduction
3. Reduce CYP2D6 substrate doses by 25-50% when initiating bupropion, particularly at doses ≥300 mg/day
4. Monitor closely for adverse effects in the first 2-4 weeks
5. Consider TDM for drugs with available assays (e.g., tricyclic antidepressants, antipsychotics)
6. For prodrugs (codeine, tramadol): Switch to alternative analgesics not requiring CYP2D6 activation

When discontinuing bupropion:

1. Anticipate loss of CYP2D6 inhibition over 1-2 weeks
2. Monitor for loss of efficacy of CYP2D6 substrates
3. May need to increase doses of CYP2D6 substrates back to pre-bupropion levels